Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1993 Mar 1;90(5):1867–1871. doi: 10.1073/pnas.90.5.1867

Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21.

A Orr-Urtreger 1, L Trakhtenbrot 1, R Ben-Levy 1, D Wen 1, G Rechavi 1, P Lonai 1, Y Yarden 1
PMCID: PMC45981  PMID: 8095334

Abstract

Neu differentiation factor (NDF/heregulin) is a 44-kDa glycoprotein that interacts with the Neu/ErbB-2 receptor tyrosine kinase to increase its phosphorylation on tyrosine residues. In vitro NDF promotes differentiation of certain mammary tumor cell lines to milk-producing cells. As a first step toward understanding the physiological role of NDF, we performed in situ hybridization analyses to determine mRNA distribution in the mouse embryo and to map the gene to human karyotypes. In 14.5-day-postcoitum mouse embryos, NDF expression is confined predominantly to the central and peripheral nervous system, including the neuroepithelium that lines the lateral ventricles of the brain, the ventral horn of the spinal cord, and the intestinal as well as dorsal root ganglia. Other tissues that contain NDF transcripts are the adrenal gland, liver, and distinct cell layers of the dermis and germinal ridge. In situ hybridization of a 3H-labeled probe to human metaphase spreads localized the NDF gene to the short arm of chromosome 8 at bands p12-p21.

Full text

PDF
1867

Images in this article

1868Fig. 1
on p.1868
1869Fig. 2
on p.1869
1870Fig. 3
on p.1870

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cohen J. A., Yachnis A. T., Arai M., Davis J. G., Scherer S. S. Expression of the neu proto-oncogene by Schwann cells during peripheral nerve development and Wallerian degeneration. J Neurosci Res. 1992 Apr;31(4):622–634. doi: 10.1002/jnr.490310406. [DOI] [PubMed] [Google Scholar]
  2. Dutrillaux B., Viegas-Pequignot E. High resolution R- and G-banding on the same preparation. Hum Genet. 1981;57(1):93–95. doi: 10.1007/BF00271176. [DOI] [PubMed] [Google Scholar]
  3. Fazioli F., Kim U. H., Rhee S. G., Molloy C. J., Segatto O., Di Fiore P. P. The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency. Mol Cell Biol. 1991 Apr;11(4):2040–2048. doi: 10.1128/mcb.11.4.2040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
  5. Goldman R., Levy R. B., Peles E., Yarden Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry. 1990 Dec 18;29(50):11024–11028. doi: 10.1021/bi00502a002. [DOI] [PubMed] [Google Scholar]
  6. Goto M., Rubenstein M., Weber J., Woods K., Drayna D. Genetic linkage of Werner's syndrome to five markers on chromosome 8. Nature. 1992 Feb 20;355(6362):735–738. doi: 10.1038/355735a0. [DOI] [PubMed] [Google Scholar]
  7. Harwerth I. M., Wels W., Marte B. M., Hynes N. E. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem. 1992 Jul 25;267(21):15160–15167. [PubMed] [Google Scholar]
  8. Holmes W. E., Sliwkowski M. X., Akita R. W., Henzel W. J., Lee J., Park J. W., Yansura D., Abadi N., Raab H., Lewis G. D. Identification of heregulin, a specific activator of p185erbB2. Science. 1992 May 22;256(5060):1205–1210. doi: 10.1126/science.256.5060.1205. [DOI] [PubMed] [Google Scholar]
  9. Holmgren L., Glaser A., Pfeifer-Ohlsson S., Ohlsson R. Angiogenesis during human extraembryonic development involves the spatiotemporal control of PDGF ligand and receptor gene expression. Development. 1991 Nov;113(3):749–754. doi: 10.1242/dev.113.3.749. [DOI] [PubMed] [Google Scholar]
  10. Kokai Y., Cohen J. A., Drebin J. A., Greene M. I. Stage- and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8498–8501. doi: 10.1073/pnas.84.23.8498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lee J., Dull T. J., Lax I., Schlessinger J., Ullrich A. HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J. 1989 Jan;8(1):167–173. doi: 10.1002/j.1460-2075.1989.tb03361.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lehväslaiho H., Lehtola L., Sistonen L., Alitalo K. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. EMBO J. 1989 Jan;8(1):159–166. doi: 10.1002/j.1460-2075.1989.tb03360.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lin C. C., Draper P. N., De Braekeleer M. High-resolution chromosomal localization of the beta-gene of the human beta-globin gene complex by in situ hybridization. Cytogenet Cell Genet. 1985;39(4):269–274. doi: 10.1159/000132156. [DOI] [PubMed] [Google Scholar]
  14. Massagué J. Transforming growth factor-alpha. A model for membrane-anchored growth factors. J Biol Chem. 1990 Dec 15;265(35):21393–21396. [PubMed] [Google Scholar]
  15. Mitelman F., Heim S. Quantitative acute leukemia cytogenetics. Genes Chromosomes Cancer. 1992 Jul;5(1):57–66. doi: 10.1002/gcc.2870050109. [DOI] [PubMed] [Google Scholar]
  16. Orr-Urtreger A., Lonai P. Platelet-derived growth factor-A and its receptor are expressed in separate, but adjacent cell layers of the mouse embryo. Development. 1992 Aug;115(4):1045–1058. doi: 10.1242/dev.115.4.1045. [DOI] [PubMed] [Google Scholar]
  17. Peles E., Bacus S. S., Koski R. A., Lu H. S., Wen D., Ogden S. G., Levy R. B., Yarden Y. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell. 1992 Apr 3;69(1):205–216. doi: 10.1016/0092-8674(92)90131-u. [DOI] [PubMed] [Google Scholar]
  18. Peles E., Lamprecht R., Ben-Levy R., Tzahar E., Yarden Y. Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation. J Biol Chem. 1992 Jun 15;267(17):12266–12274. [PubMed] [Google Scholar]
  19. Peles E., Levy R. B., Or E., Ullrich A., Yarden Y. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J. 1991 Aug;10(8):2077–2086. doi: 10.1002/j.1460-2075.1991.tb07739.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Perantoni A. O., Rice J. M., Reed C. D., Watatani M., Wenk M. L. Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea. Proc Natl Acad Sci U S A. 1987 Sep;84(17):6317–6321. doi: 10.1073/pnas.84.17.6317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Perry P., Wolff S. New Giemsa method for the differential staining of sister chromatids. Nature. 1974 Sep 13;251(5471):156–158. doi: 10.1038/251156a0. [DOI] [PubMed] [Google Scholar]
  22. Regenstreif L. J., Rossant J. Expression of the c-fms proto-oncogene and of the cytokine, CSF-1, during mouse embryogenesis. Dev Biol. 1989 May;133(1):284–294. doi: 10.1016/0012-1606(89)90319-9. [DOI] [PubMed] [Google Scholar]
  23. Salk D., Au K., Hoehn H., Stenchever M. R., Martin G. M. Evidence of clonal attenuation, clonal succession, and clonal expansion in mass cultures of aging Werner's syndrome skin fibroblasts. Cytogenet Cell Genet. 1981;30(2):108–117. doi: 10.1159/000131597. [DOI] [PubMed] [Google Scholar]
  24. Schechter A. L., Stern D. F., Vaidyanathan L., Decker S. J., Drebin J. A., Greene M. I., Weinberg R. A. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984 Dec 6;312(5994):513–516. doi: 10.1038/312513a0. [DOI] [PubMed] [Google Scholar]
  25. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  26. Stancovski I., Hurwitz E., Leitner O., Ullrich A., Yarden Y., Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8691–8695. doi: 10.1073/pnas.88.19.8691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Stern D. F., Heffernan P. A., Weinberg R. A. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol. 1986 May;6(5):1729–1740. doi: 10.1128/mcb.6.5.1729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990 Apr 20;61(2):203–212. doi: 10.1016/0092-8674(90)90801-k. [DOI] [PubMed] [Google Scholar]
  29. Vogelstein B., Fearon E. R., Hamilton S. R., Kern S. E., Preisinger A. C., Leppert M., Nakamura Y., White R., Smits A. M., Bos J. L. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988 Sep 1;319(9):525–532. doi: 10.1056/NEJM198809013190901. [DOI] [PubMed] [Google Scholar]
  30. Wada T., Qian X. L., Greene M. I. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell. 1990 Jun 29;61(7):1339–1347. doi: 10.1016/0092-8674(90)90697-d. [DOI] [PubMed] [Google Scholar]
  31. Walsh C., Cepko C. L. Clonally related cortical cells show several migration patterns. Science. 1988 Sep 9;241(4871):1342–1345. doi: 10.1126/science.3137660. [DOI] [PubMed] [Google Scholar]
  32. Wen D., Peles E., Cupples R., Suggs S. V., Bacus S. S., Luo Y., Trail G., Hu S., Silbiger S. M., Levy R. B. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell. 1992 May 1;69(3):559–572. doi: 10.1016/0092-8674(92)90456-m. [DOI] [PubMed] [Google Scholar]
  33. Yarden Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2569–2573. doi: 10.1073/pnas.87.7.2569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Yarden Y., Peles E. Biochemical analysis of the ligand for the neu oncogenic receptor. Biochemistry. 1991 Apr 9;30(14):3543–3550. doi: 10.1021/bi00228a027. [DOI] [PubMed] [Google Scholar]
  35. Yarden Y., Weinberg R. A. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proc Natl Acad Sci U S A. 1989 May;86(9):3179–3183. doi: 10.1073/pnas.86.9.3179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. van der Bosch K., Becker I., Savelyeva L., Brüderlein S., Schlag P., Schwab M. Deletions in the short arm of chromosome 8 are present in up to 90% of human colorectal cancer cell lines. Genes Chromosomes Cancer. 1992 Jul;5(1):91–95. doi: 10.1002/gcc.2870050114. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES